Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 30, 2015

View Archived Issues

Serina initiates phase I trial of SER-214 in patients with Parkinson's disease

Valor initiates first-in-human study of IGN-002 for NHL

Rovalpituzumab tesirine from Stemcentrx receives FDA orphan drug designation

Identification of CSF biomarkers for atypical parkinsonian syndromes

Novel preclinical model for cancer cachexia

Agios Pharmaceuticals starts phase I trial of pyruvate kinase deficiency candidate

Bayer plans phase I trial of BAY-1251152 in patients with advanced cancers

Aimmune Therapeutics moves peanut allergy therapeutic AR-101 into phase III

City of Hope discloses SENP inhibitors that prevent HIV genome integration

Amarantus requests rare pediatric disease and orphan drug designations

ADCT-402 shows antitumor activity against CD19-expressing B-cell malignancies

Midatech Pharma completes acquisition of Zuplenz

Vitae initiates proof-of-concept study of VTP-38543 in atopic dermatitis

Novel reversible bromodomain inhibitor shows promise for AML

Novel BET bromodomain inhibitor from Epigenetix a potential clinical candidate

Entospletinib is well tolerated in iNHL patients

Nanjing Sanhome Pharmaceutical patents EGFR inhibitors

French scientists describe GPBAR1 agonists

Kyoto Pharmaceutical Industries reports napabucasin prodrugs

Bristol-Myers Squibb presents nAChR alpha7 agonists

Adamed develops p53-MDM2 interaction inhibitors

Takeda Pharmaceutical divulges muscarinic M1 PAMs

Shionogi reports development of antifungal agents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...